Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2001

View Archived Issues

Argatroban sNDA filed for HIT patients undergoing PCI

Ivax joins forces with Harvard Medical School affiliate in CF research

SR Pharma and Corixa broaden autoimmune diseases agreement

Solvay launches Teveten in Canada for hypertension

United Therapeutics forms new company focused on gene therapy

Phase III results with Metvix PDT for primary BCC reported as positive

Aminoacyl-tRNA synthetase pursued as potential target for new antibacterial agents

Nonacylguanidine compound characterized as potent and selective NHE1 inhibitor

Prospective trial compares efficacy of teprenone and rabeprazole against NSAID-induced GI lesions

Cholesterol-lowering effects of Sch-48461 demonstrated in primary hypercholesterolemia

DITPA improves abnormal SR Ca2+ transport and protein expression following myocardial infarction

Expanded phase III trial program in bipolar disorder announced for Seroquel

Cor, Schering-Plough and Genentech to copromote Integrilin, TNKase and Activase

Lorus Therapeutics' Virulizin shows better antitumor activity than Taxol in preclinical studies

Major functional genomics collaboration in oncology formed in Europe

Roche and Genentech enter agreement with OSI to develop and commercialize OSI-774

AVI BioPharma receives grant to develop NeuGene-based prostate cancer therapeutics

Aventis sells U.S. and Canadian rights to Cardizem products to Biovail

Successful completion of phase I trial with Isotechnika's new immunosuppressant

Ligand receives milestone payment from Wyeth-Ayerst; TSE-424 development continues

GnRH receptor antagonists designed by Neurocrine Biosciences group

New 3-pyridyl-4-arylpyrroles useful for inflammatory and AIDS-related disorders

Important advances in the Lundbeck pipeline during 2000

Novel heterocyclic compounds with broad pharmacological activity described by P&G

Roche presents new imidazodiazepine derivative with advantageous profile

PGE1 derivatives synthesized at Taisho inhibit vascular smooth muscle cell proliferation

Potential anticoagulants/antithrombotics under study at Yamanouchi

Bradycardic tetrahydroisoquinolines prepared by Yamanouchi research team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.